Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 413-419

  Recchia, Francesco ^a,b,e   Candeloro, Giampiero ^a   Di Staso, Mario ^c   Necozione, Stefano ^c   Bisegna, Roberta ^a   Bratta, Massimo ^b   Tombolini, Vincenzo ^c   Rea, Silvio ^b,d  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Carlo Ferri   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e NONE   (Italy)

Author keywords

13 cis retinoic acid; Advanced head and neck cancer; Cisplatin; Docetaxel; Ifosfamide; Interleukin 2

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; IFOSFAMIDE; INTERLEUKIN 2; ISOTRETINOIN; MESNA; VASCULOTROPIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOTHERAPY; INFECTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NATURAL KILLER CELL; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSORY NEUROPATHY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CD4-CD8 RATIO; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTES; TAXOIDS;

EID: 42649096615     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816d1d8e     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, et al. American Cancer Society. Cancer statistics. CA Cancer J Clin. 2006;56:106-130.
2. Parkin M, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. GLOBOCAN 2002. http:/www-dep.iarc.fr.
4. Chin D, Boyle GM, Porceddu S, et al. Head and neck cancer: past present and future. Expert Rev Anticancer Treat. 2006;6:1111-1118.
5. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245-1251.
6. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562-3567.
7. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
8. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25:2178-2183.
9. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
10. Vermorken J, Mesia R, Vega Villegas ME, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy-Results of a randomized phase III (Extreme) study. Proc Am Soc Clin Oncol. 2006;25:abstract no. 6091.
11. Recchia F, Sica G, De Filippis S, et al. Chemo-immunotherapy in advanced head and neck cancer. Anticancer Res. 1999;19:773-777.
12. Recchia F, Lalli A, Lombardo M, et al. Ifosfamide, cisplatin and 13-cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck. A phase I-II study. Cancer. 2001;92:814-821.
13. Recchia F, Saggio G, Cesta A, et al. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Anticancer Res. 2006;26:2317-2324.
14. Whiteside TL. Tumor-infiltrating Lymphocytes in Human Solid Tumors. Austin, TX: R. G. Landes; 1993.
15. Reichert TE, Rabinowich H, Johnson JT, et al. Human immune cells in the tumor microenvironment: mechanism responsible for signaling and functional defects. J Immunother. 1998;21:295-306.
16. Saito T, Kuss I, Dworacki G, et al. Spontaneous ex vivo apoptosis of peripheral blood cells in patients with head and neck cancer. Clinical Cancer Res. 1999;5:1263-1273.
17. Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007;25:862-868.
18. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92:556-568.
19. Sauter ER, Nesbit M, Watson JC, et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999;5:775-782.
20. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963-2970.
21. Recchia F, De Filippis S, Rosselli M, et al. Phase IB study of subcutaneously administered Interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res. 2001;7:1251-1257.
22. Recchia F, Saggio G, Nuzzo A, et al. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J Immunother. 2006;29:87-94.
23. Recchia F, Saggio G, Cesta A, et al. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int J Oncol. 2005;27:1039-1046.
24. Recchia F, Saggio G, Cesta A, et al. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol Immunother. 2007;56:699-708.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
26. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478-3483.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005;23: 8646-8654.
30. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8: 2553-2562.
31. + T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:5101-5110.
32. + effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007;29:120-127.
33. Moloney FJ, Kelly PO, Kay EW, et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg. 2004;30: 674-678.
34. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:1325-1330.
35. Schoffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol. 1999;10:119-122.
36. Glisson BS, Murphy BA, Frenette G, et al. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002; 20:1593-1599.